Satyajit Kumar Mitra - 01 Nov 2022 Form 4 Insider Report for Peak Bio, Inc.

Role
Executive Director, Head of Oncology
Signature
/s/ Satyajit Kumar Mitra
Issuer symbol
N/A
Transactions as of
01 Nov 2022
Net transactions value
$0
Form type
4
Filing time
03 Nov 2022, 21:53:12 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PKBO Stock Option (Right to Buy) Award +18,647 18,647 01 Nov 2022 Common Stock 18,647 $6.10 Direct F1
transaction PKBO Stock Option (Right to Buy) Award +31,700 31,700 01 Nov 2022 Common Stock 31,700 $8.05 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement (the "Business Combination Agreement") between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea ("Legacy Peak Bio"), and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea. These stock options represent Legacy Peak Bio stock options and were initially granted to the Reporting Person on June 12, 2019 and are fully vested.
F2 Received pursuant to the consummation of the transactions contemplated by the Business Combination Agreement. These stock options represent Legacy Peak Bio stock options and were initially granted to the Reporting Person on January 26, 2022. The stock options become fully vested and exercisable after two years from the initial date of grant, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

Executive Director, Head of Oncology